Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 33 Issue 3
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2015  >  33(3): 258-260,268

KOU Xiaoxia, DING Yongmei, HUANG Yao, YUAN Zhengang, QIAN Qijun. Changes of regulatory T cells in peripheral blood after gemcitabine chemotherapy for pancreatic cancer patients[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(3): 258-260,268. doi: 10.3969/j.issn.1006-0111.2015.03.018
Citation: KOU Xiaoxia, DING Yongmei, HUANG Yao, YUAN Zhengang, QIAN Qijun. Changes of regulatory T cells in peripheral blood after gemcitabine chemotherapy for pancreatic cancer patients[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(3): 258-260,268. doi: 10.3969/j.issn.1006-0111.2015.03.018
shu

Changes of regulatory T cells in peripheral blood after gemcitabine chemotherapy for pancreatic cancer patients

doi: 10.3969/j.issn.1006-0111.2015.03.018

  • Department of Biotherapy, Eastern Hepatobiliary Surgical Hospital, Shanghai 200438, China

  • Received Date: 2015-01-01
  • Rev Recd Date: 2015-04-17
  • Objective To investigate the influence of gemcitabine chemotherapy on levels of regulatory T cells(Tregs) in peripheral blood for patients with pancreatic cancer and provide evidence and reference for improving the efficacy of adoptive immunotherapy. Methods 32 patients were enrolled in this study from January 2012 to October 2014, among whom 16 received gemcitabine chemotherapy combined with adoptive immunotherapy(gemcitabine group), the other 16 patients received adoptive immunotherapy only(control group).The level of Tregs in peripheral blood, side effect and overall survival were observed before and after the therapy. Results The number of Tregs in peripheral blood was significantly decreased after gemcitabine chemotherapy, and it was also lower than that of the control group. The overall survival time of the gemcitabine group was 1.3 mo longer than the control group(10.0 mo vs 8.7 mo). Conclusion Therapeutic regimen of gemcitabine can remarkly deplete Tregs in peripheral blood of patients with pancreatic cancer, effectively regulate tumor immune tolerance, and improve the efficacy of adoptive immunotherapy.
  • [1] Trouilloud I,Dubreuil O,Boussaha T,et al.Medical treatment pancreatic cancer:new hopes after 10 years of gemcitabine[J].Clin Res Hepatol Gastroenterol,2011,35(5):364-374.
    [2] ShevchenkoI,Karakhanova S, Soltek S,et al.Low-dose gemcetabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer[J].Int J Cancer,2013,133(1):98-107.
    [3] Burris HA,Moore MJ,Andersen J,et al.Improvement in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol,1997,15(6):2403-2413.
    [4] Hiraoka N,Onozato K,Kosuge T,et al.Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions[J].Clin Cancer Res,2006,12:5423-5434.
    [5] Ikemoton T,Yamaguchi T,Morine Y,et al.Clinical roles of increased populations of Foxp3+ CD4+ T cells in peripheral blood from advanced pancreatic cancer patients[J].Pancreas,2006,33:386-390.
    [6] Shindo Y, Hazama S, Maeda Y,et al.Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcetabine for unresectable pancreatic cancer[J].J Translat Med,2014,12:175.
    [7] Gabitass RF,Annels NE,Stocken DD,et al.Elevated myeloid-derived suppressor cells in pancreatic,esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13[J].Cancer Immunol Immunother,2011,60:1419-1430.
    [8] Ghansah T, Vohra N, Kinney K,et al.Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma[J].Cancer Immunol Immunother,2013,62:1083-1091.
    [9] 高 强,邱双健,樊 嘉.CD4+ CD25+ FOXP3+调节性T细胞在肿瘤免疫逃逸中的作用研究进展[J].中国癌症杂志,2007,17(8):657-662.
    [10] 卢晓婷,刘俊田. CD4+ CD25+调节性T细胞在肿瘤免疫及化疗方面的研究进展[J].中国肿瘤临床,2008,35(11):656-660.
    [11] Homma Y,Tangiguchi K,Nakazawa M,et al.Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer[J].Clini Translat Oncol,2014,16:330-335.
    [12] Bunt SK,Mohr AM,Bailey JM,et al.Rosiglitazone and gemcitabine in combination reduces immune suppression and modulates T populations in pancreatic cancer[J].Cancer Immunol Immunother,2013,62:225-236.
  • 加载中
通讯作者: 陈斌, [email protected]
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(3417) PDF downloads(395) Cited by()

Related
Proportional views

Changes of regulatory T cells in peripheral blood after gemcitabine chemotherapy for pancreatic cancer patients

doi: 10.3969/j.issn.1006-0111.2015.03.018
  • Department of Biotherapy, Eastern Hepatobiliary Surgical Hospital, Shanghai 200438, China
  • Received Date: 2015-01-01
  • Rev Recd Date: 2015-04-17

Abstract: Objective To investigate the influence of gemcitabine chemotherapy on levels of regulatory T cells(Tregs) in peripheral blood for patients with pancreatic cancer and provide evidence and reference for improving the efficacy of adoptive immunotherapy. Methods 32 patients were enrolled in this study from January 2012 to October 2014, among whom 16 received gemcitabine chemotherapy combined with adoptive immunotherapy(gemcitabine group), the other 16 patients received adoptive immunotherapy only(control group).The level of Tregs in peripheral blood, side effect and overall survival were observed before and after the therapy. Results The number of Tregs in peripheral blood was significantly decreased after gemcitabine chemotherapy, and it was also lower than that of the control group. The overall survival time of the gemcitabine group was 1.3 mo longer than the control group(10.0 mo vs 8.7 mo). Conclusion Therapeutic regimen of gemcitabine can remarkly deplete Tregs in peripheral blood of patients with pancreatic cancer, effectively regulate tumor immune tolerance, and improve the efficacy of adoptive immunotherapy.

KOU Xiaoxia, DING Yongmei, HUANG Yao, YUAN Zhengang, QIAN Qijun. Changes of regulatory T cells in peripheral blood after gemcitabine chemotherapy for pancreatic cancer patients[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(3): 258-260,268. doi: 10.3969/j.issn.1006-0111.2015.03.018
Citation: KOU Xiaoxia, DING Yongmei, HUANG Yao, YUAN Zhengang, QIAN Qijun. Changes of regulatory T cells in peripheral blood after gemcitabine chemotherapy for pancreatic cancer patients[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(3): 258-260,268. doi: 10.3969/j.issn.1006-0111.2015.03.018
shu

    HTML

Reference (12)

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return